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Abstract
Background: Triglyceride/high-density lipoprotein-cholesterol (TG/HDL-C) ratio was a surrogate marker of IR; however,
the relationship of TG/HDL-C with IR might vary by ethnicity. This study aims to investigate whether lipid ratios-TG/HDL-C,
cholesterol/high-density lipoprotein-cholesterol (TC/HDL-C) ratio, low-density lipoprotein-cholesterol/high-density
lipoprotein-cholesterol (LDL-C/HDL-C)) could be potential clinical markers of insulin resistance (IR) and β cell
function and further to explore the optimal cut-offs in a Chinese population with different levels of glucose tolerance.
Methods: Four hundred seventy-nine subjects without a history of diabetes underwent a 75 g 2 h Oral Glucose
Tolerance Test (OGTT). New-onset diabetes (n = 101), pre-diabetes (n = 186), and normal glucose tolerance (n = 192)
were screened. IR was defined by HOMA-IR > 2.69. Based on indices (HOMA-β, early-phase disposition index [DI30],
(ΔIns30/ΔGlu30)/HOMA-IR and total-phase index [DI120]) that indicated different phases of insulin secretion, the
subjects were divided into two groups, and the lower group was defined as having inadequate β cell compensation.
Logistic regression models and accurate estimates of the areas under receiver operating characteristic curves (AUROC)
were obtained.
Results: In all of the subjects, TG/HDL, TC/HDL-C, LDL-C/HDL-C, and TG were significantly associated with IR. The
AUROCs of TG/HDL-C and TG were 0.71 (95 % CI: 0.66–0.75) and 0.71 (95 % CI: 0.65–0.75), respectively. The optimal
cut-offs of TG/HDL-C and TG for IR diagnosis were 1.11 and 1.33 mmol/L, respectively. The AUROCs of TC/HDL-C and
LDL-C/HDL-C were 0.66 and 0.65, respectively, but they were not acceptable for IR diagnosis. TG/HDL-C,LDL-C/HDL-C
and TG were significantly associated with HOMA-β, but AUROCs were less than 0.50; therefore, the lipid ratios could
not be predictors of basal β cell dysfunction. None of the lipid ratios was associated with early-phase insulin secretion.
Only TG/HDL-C and TG were significantly correlated with total-phase insulin secretion, but they also were not
acceptable predictors of total-phase insulin secretion (0.60 < AUROC < 0.70).
Conclusions: In a Chinese population with different levels of glucose tolerance, TG/HDL-C and TG could be the
predictors of IR. The lipid ratios could not be reliable makers of β cell function in the population.
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Background
Insulin resistance (IR) and islet β cell dysfunction are
two major risks in the pathogenesis of type 2 diabetes.
The hyperinsulinemic/euglycemic clamp, which is regarded
as the gold standard method to detect IR, is impractical for
large clinical research studies [1]. IR is often accompanied
by dyslipidemia. In pre-diabetic and diabetic patients,
hyperglycemia was accompanied by dyslipidemia [2], and
even in normoglycemic people [3]. Previous studies have
reported that the triglyceride/high-density lipoprotein-
cholesterol (TG/HDL-C) ratio was a surrogate marker of
IR [4–6]; however, the relationship of TG/HDL-C with IR
might vary by ethnicity [5, 7, 8]. The TG/HDL-C ratio
could predict IR in Caucasians, while in African Americans,
there remain conflicts in the association between TG/HDL-
C and IR [9, 10], and several studies in Chinese subjects
have suggested that TG/HDL-C could be a predictor of IR
[11–14]. In contrast, the accurate assessment of islet β cell
function is much more difficult than the assessment of
insulin sensitivity [15]. Several studies have attempted to
investigate the relationship between TG/HDL-C and β cell
function. In normoglycemic African American women,
TG/HDL-C was inversely associated with β cell function,
suggesting that the TG/HDL-C ratio could be a simple tool
for effectively identifying African Americans at risk for
diabetes [16]. In our previous cohort study, a high baseline
log (TG)/HDL-C ratio predicted rapid progression of islet β
cell function [17]. However, the studies mentioned above
focused on only one glucose tolerance status ranging from
normal plasma glucose to diabetes. In fact, IR exists
throughout all the glucose tolerance status, and whether
TG/HDL-C could be a surrogate marker for IR and β cell
function in populations with different levels of glucose
tolerance remains unknown.
This study aimed to develop a simple predictive marker
as a clinical tool for the evaluation of IR and β cell
function in a Chinese population with different levels of
glucose tolerance, ranging from normoglycemia to dia-
betes, to investigate whether lipid ratios could be potential
clinical markers of IR and β cell function and to further
explore the optimal cut-offs.
Methods
Study population
All subjects were recruited from a type 2 diabetes pro-
ject in a Beijing suburb in China between March 2014
and January 2015. Four hundred eighty-nine subjects
without a history of diabetes underwent a 75 g OGTT.
The 75 g OGTT was conducted after an overnight fast
(> 10 h). Blood samples were collected at 0 min, 30, 60
and 120 min following the OGTT. The glucose tolerance
status of each subject was classified based on the 1999
criteria of the WHO: a normal glucose tolerance (NGT),
indicated by fasting plasma glucose (FPG) < 6.1 mmol/L
and 2 h postprandial glucose (2 h PG) < 7.8 mmol/L; pre-
diabetes, indicated by impaired fasting glucose (IFT):
6.1 mmol/L ≤ FPG < 7.0 mmol/L and 2 h PG < 7.8 mmol/
L; impaired glucose tolerance (IGT), indicated by FPG <
6.1 mmol/L and 7.8 ≤ 2 h PG <11.1 mmol/L; or IFT +
IGT, with T2DM indicated by FPG ≥ 7.0 mmol/L or 2 h
PG ≥ 11.1 mmol/L.
The subjects who have a current history of cigarette
smoking and alcohol drinking were excluded, and sub-
jects with serious diseases such as heart disease, stroke,
kidney disease, liver disease, inflammatory disease were
also excluded. Ten subjects who were on steroids or
who were taking drugs interfering with lipid metabolism
such as lipid-lowering agents, diuretics, β-blockers, fish
oil were excluded. On the basis of the OGTT results,
subjects with NGT (n = 101), pre-diabetes (n = 186), and
diabetes (n = 192) were selected for this study. The study
protocol was approved by the Ethics Committee of
Peking Union Medical College Hospital. The subjects
voluntarily signed informed consent forms.
Clinical measurement
A standardized medical history and accurate physical
examination were undertaken in all of the subjects before
a 75 g OGTT was administered. Measurements of waist
circumference (WC) (midway between the iliac crest and
the costal margin) and hip circumference (HC) (at the
level of the trochanters) were performed twice by the
same observer, and the mean value was recorded. Weight
and height were measured without shoes in light clothing,
and body mass index (BMI) was calculated by dividing the
body weight in kilograms by square of the height in
meters. Blood pressure measurements were obtained
twice with a standard mercury sphygmomanometer with
the subjects at rest, and the mean value was calculated.
Overweight and obesity were defined as 24 kg/m2 ≤ BMI
< 28 kg/m2 and BMI ≥ 28 kg/m2, respectively [18].
Biochemical measurements
Plasma glucose was measured by glucose oxidase assay.
TC, TG, HDL-C, and LDL-C were determined using an
automated analyzer. Serum insulin and C peptide were
measured by chemiluminescent enzyme immunoassay.
HbA1c analysis was performed by high-performance
liquid chromatography (intra-assay CV < 3 %, inter-assay
CV < 10 %).
Assessment of IR
Homeostatic model assessment of insulin resistance was
calculated as the following formula: (HOMA-IR). IR was
defined as HOMA-IR >2.69, based on an epidemiology
survey conducted in China [19].
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Assessment of β cell function
The homeostasis model assessment of insulin secretion
(HOMA-β) was calculated as basal insulin release [20].
Early-phase insulin release was calculated as the total in-
sulin area under the curve divided by the total glucose
area under the curve during the first 30 min of the
OGTT (InsAUC30/GluAUC30), which was shown to have
a strong correlation with first-phase insulin secretion
[21]. Insulin secretion relative to insulin sensitivity (ISIM:
Matsuda insulin sensitivity index) was expressed as the
disposition index (DI), calculated as: early-phase DI30
= [InsAUC30/GluACU30] × ISIM, (ΔIns30/ΔGlu30)/HOMA
-IR and total-phase DI120 = [InsAUC120/GluACU120] × ISIM.
Another formula for assessing early-phase insulin release
was: (ΔIns30/ΔGlu30)/HOMA-IR.
There were no prior data on the alternate cut-offs for
inadequate β cell compensation in Chinese. In the present
study, subjects with pre-diabetes/diabetes accounted for
59.9 % of the sample; therefore, based on the indices
above, the subjects were divided into two groups. We
defined the lower group as having inadequate β cell
compensation.
Statistical analysis
All of the statistical analyses were performed using SPSS
software, version 17.0 (Chicago, IL, USA). The data are
presented as the means ± SDs. Parameters not normally
distributed were transformed. Categorical data were
analyzed using the χ2 test. The significance of the mean
differences was tested by the t test and ANOVA (followed
by Bonferroni’s post hoc pairwise comparisons).
All P- values were two-sided, and P <0.05 was consid-
ered statistically significant.
To explore the associations among the lipid ratios
(TG/HDL-C, TC/HDL-C, LDL-C/HDL-C), TG and IR,
and β cell function, logistic regression models were used,
and odds ratios (ORs) and 95 % confidence interval
(CIs) were calculated. First, single factor analysis was
conducted, and lipid ratios and TG, sex, age, BMI, WC,
and HC were used as independent variables; then, in the
multivariable analysis model, the confounding factors
that were significantly associated with IR and β cell
function in single factor analysis were added.
The lipid ratios that were significantly associated with
IR or β cell function in the multivariable analysis model
were used to estimate the area under the receiver oper-
ating characteristic (AUROC) curve for analysis. The
AUROCs were also adjusted for the covariates used in
the logistic models. Based on the AUROCs, the diagnos-
tic value of the lipid ratios and TG were assessed: an
AUROC ≤ 0.5 was considered no discrimination, an
AUROC between 0.7 and 0.8 was considered acceptable,
an AUROC between 0.8 and 0.9 was considered excel-
lent, and an AUROC > 0.9 was considered outstanding
[22]. Youden’s index was calculated as (specificity +
sensitivity − 1) and was used to select the optimal cut-offs
for each lipid ratio and TG.
Results
1. Clinical characteristics of subgroups divided by
plasma glucose profiles and insulin resistance
According to the plasma glucose levels, the subjects
were divided into three groups: normal glucose tolerance
(NGT), pre-diabetes and diabetes. The characteristics
among the three groups are presented in Table 1. The
pre-diabetes and diabetes subjects had older ages, larger
BMIs, waist circumferences, hip circumferences, propor-
tions with overweight/obesity and higher SBP than the
normal glycemic tolerance subjects. In both pre-diabetes
and diabetes subjects, insulin (30 min), C peptide
(30 min), HOMA-β, DI30, DI120, and (ΔIns30/ΔGlu30)/
HOMA-IR were significantly lower than those in the
normal glycemic subjects. The diabetes subjects had
higher lipid profiles (TG, TG/HDL-C, TC/HDL-C, LDL-
C/HDL-C) and HOMA-IR than the normal glycemic
and pre-diabetes subjects.
According to IR, the subjects were divided into an
insulin resistance group (HOMA-IR >2.69) and insulin
sensitivity group (HOMA-IR ≤2.69). The characteristics
are presented in Table 2. There was no significant differ-
ence in age, sex, blood pressure, or total cholesterol
between the groups. The proportions with diabetes and
overweight/obesity, the lipid profiles (TG, LDL-C, TG/
HDL-C, TC/HDL-C, LDL-C/HDL-C), fasting and post-
prandial plasma glucose, insulin, and C peptide were
much higher in the HOMA-IR >2.69 group. HOMA-β,
which reflects the basal insulin secretion, was signifi-
cantly higher in the elevated HOMA-IR group, while
DI30 and (ΔIns30/ΔGlu30)/HOMA-IR, which indicate
early-phase insulin secretion, and DI120, which reflects
total-phase insulin secretion, were significantly lower in
the elevated HOMA-IR group.
2. Association of lipid ratios with IR in the population
with different levels of glucose tolerance
In the whole population with continuous glucose toler-
ance, TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, TG, and
HDL-C were significantly associated with IR. Single factor
analysis showed that sex, BMI, waist circumference, hip
circumference, and plasma glucose were associated with
IR (Table 3), and these confounding factors were included
in the binary multivariable logistic regression model
analysis, in which TG/HDL-C, TC/HDL-C, LDL-C/HDL-
C, and TG were significantly associated with IR, and the
association was independent of these confounding factors
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(Table 4). Therefore, the next step was to explore whether
TG/HDL-C, TC/HDL-C, LDL-C/HDL-C, and TG could
be good predictors of IR.
In women, TG/HDL-C, TC/HDL-C, LDL-C/HDL-C,
TG, and HDL-C were significantly associated with IR,
and in men, TG/HDL-C and TG were associated with
IR, independent of age, BMI, waist circumference, hip
circumference, and plasma glucose profile (Table 4).
3. Comparison of area under ROCs and optimal
cut-offs for predictors of IR in a population with
different levels of glucose tolerance
Table 1 Characteristics in different glucose tolerance status
Characteristic NGT Pre-diabetes Diabetes P-value
N = 192 N = 186 N = 101
Female (%) 135 (70.31) 115 (61.83) 60 (59.41) 0.000*
Age, years 48.77 ± 11.55 55.36 ± 10.22 54.54 ± 9.89 0.000*
BMI, kg/m2 24.98 ± 3.46 26.74 ± 3.74 26.86 ± 4.15 0.000*
Overweight/obesity (%) 114 (59.38) 136 (73.12) 80 (79.21) 0.000*
Waist circumference, cm 84.64 ± 9.75 88.48 ± 9.19 88.31 ± 9.54 0.000*
Hip circumference, cm 90.17 ± 9.88 93.52 ± 8.88 93.13 ± 12.26 0.003*
Systolic BP, mm Hg 123.59 ± 19.08 129.12 ± 15.92 131.45 ± 20.89 0.001*
Diastolic BP, mm Hg 75.54 ± 9.93 76.50 ± 10.02 77.06 ± 10.76 0.429
HbA1c 5.26 ± 0.29 5.71 ± 0.33 6.87 ± 1.42 0.000*
Fasting plasma glucose (PG), mmol/L 5.45 ± 0.35 6.09 ± 0.48 8.48 ± 2.77 0.000*
PG 30’, mmol/L 8.96 ± 1.93 10.71 ± 2.01 14.78 ± 3.97 0.000*
PG 60’, mmol/L 7.57 ± 1.98 10.09 ± 2.82 16.73 ± 4.92 0.000*
PG 120’, mmol/L 5.86 ± 1.18 7.61 ± 1.76 14.92 ± 5.79 0.000*
Ln (Ins 0’, mU/L) 2.19 ± 0.49 2.31 ± 0.51 2.40 ± 0.65 0.004*
Ln (Ins 30’, mU/L) 4.28 ± 0.67 4.19 ± 0.65 3.65 ± 0.83 0.000*
Ln (Ins 60’, mU/L) 4.09 ± 0.66 4.29 ± 0.69 4.05 ± 0.90 0.008*
Ln (Ins 120’, mU/L) 3.44 ± 0.72 3.87 ± 0.78 3.96 ± 0.96 0.000*
Ln (C peptide 0’, ng/mL) 0.18 ± 0.36 0.36 ± 0.39 0.40 ± 0.48 0.000*
Ln (C peptide 30’, ng/mL) 1.63 ± 0.42 1.57 ± 0.42 1.15 ± 0.59 0.000*
Ln (C peptide 60’, ng/mL) 1.74 ± 0.44 1.84 ± 0.90 1.58 ± 0.61 0.000*
Ln (C peptide 120’, ng/mL) 1.47 ± 0.42 1.76 ± 0.44 1.71 ± 0.63 0.000*
InsAUC30/GluAUC30
(mU/mmol)
6.84 ± 2.36 5.72 ± 2.41 3.11 ± 1.72 0.000*
InsAUC120/GluAUC120 (mU/mmol) 8.39 ± 2.77 9.21 ± 2.02 5.04 ± 2.38 0.000*
Ln HOMA-IR 0.79 ± 0.46 1.02 ± 0.50 1.38 ± 0.68 0.000*
Sqrt HOMA-β 9.99 ± 2.55 9.20 ± 2.43 7.68 ± 2.86 0.000*
Sqrt DI30 24.91 ± 4.90 19.58 ± 4.64 11.97 ± 4.18 0.000*
Sqrt DI120 27.91 ± 3.84 23.39 ± 6.78 15.06 ± 6.01 0.000*
Ln [(ΔIns30/ΔGlu30)/HOMA-IR] 2.32 ± 0.78 1.76 ± 0.71 0.85 ± 0.59 0.000*
Total cholesterol (TC), mmol/L 5.26 ± 1.04 5.64 ± 1.01 5.61 ± 0.97 0.001*
Log (triglyceride [TG]), mmol/L 0.09 ± 0.27 0.20 ± 0.24 0.26 ± 0.26 0.000*
Log (HDL-C, mmol/L) 0.11 ± 0.10 0.10 ± 0.10 0.08 ± 0.09 0.013*
LDL-C, mmol/L 2.67 ± 0.74 2.96 ± 0.69 2.91 ± 0.66 0.000*
Log (TG/HDL-C) −0.02 ± 0.32 0.10 ± 0.29 0.18 ± 0.30 0.000*
TC/HDL-C 4.08 ± 1.02 4.50 ± 0.91 4.66 ± 0.85 0.000*
LDL-C/HDL-C 2.09 ± 0.71 2.37 ± 0.64 2.43 ± 0.60 0.000*
* Significant results: p < 0.05
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In the study population, the AUROCs for TG/HDL-C
and TG were 0.71 (95 % CI: 0.66–0.75) and 0.71 (95 %
CI: 0.65–0.75), respectively (Table 5, Fig. 1), and the
optimal cut-offs for TG/HDL-C and TG were 1.11
(sensitivity: 70.1 %, specificity: 66.1 %) and 1.33 (sensitiv-
ity: 69.2 %, specificity: 61.9 %). TG/HDL-C and TG (the
AUROC >0.70) were acceptable predictors of IR defined
by HOMA-IR. The AUROCs for TC/HDL-C (0.60 <
Table 2 Characteristics of insulin sensitivity vs. insulin resistance
Characteristic Insulin sensitivity Insulin resistance P-value
HOMA-IR≤ 2.69 HOMA-IR > 2.69
N = 241 N = 238
Diabetes (%) 29 (12.03) 72 (30.25) 0.000*
Pre-diabetes (%) 87 (36.10) 99 (41.60) 0.217
NGT (%) 125 (51.87) 67 (28.15) 0.000
Female (%) 153 (63.49) 158 (66.39) 0.468
Age, years 53.06 ± 10.99 51.92 ± 11.25 0.267
BMI, kg/m2 24.39 ± 3.13 27.76 ± 3.68 0.000*
Overweight/obesity (%) 124 (51.45) 206 (86.55) 0.000*
Waist circumference, cm 83.96 ± 9.38 89.88 ± 8.97 0.000*
Hip circumference, cm 89.30 ± 9.38 89.88 ± 8.97 0.000*
Systolic BP, mm Hg 127.22 ± 19.17 127.65 ± 18.03 0.804
Diastolic BP, mm Hg 75.83 ± 10.19 76.83 ± 10.11 0.391
HbA1c% 5.58 ± 0.76 5.97 ± 1.04 0.000*
Fasting plasma glucose, mmol/L 5.90 ± 1.40 6.78 ± 1.95 0.000*
Postprandial glucose (PG 30’), mmol/L 10.06 ± 2.97 11.67 ± 3.47 0.000*
PG 60’, mmol/L 9.42 ± 3.97 11.54 ± 4.99 0.000*
PG 120’, mmol/L 7.44 ± 3.56 9.44 ± 5.15 0.000*
Ln (Ins 0’, mU/L) 1.88 ± 0.33 2.69 ± 0.36 0.000*
Ln (Ins 30’, mU/L) 3.83 ± 0.67 4.41 ± 0.69 0.000*
Ln (Ins 60’, mU/L) 3.84 ± 0.62 4.48 ± 0.46 0.000*
Ln (Ins 120’, mU/L) 3.37 ± 0.73 4.07 ± 0.70 0.000*
Ln (C peptide 0’, ng/mL) 0.02 ± 0.28 0.58 ± 0.31 0.000*
Ln (C peptide 30’, ng/mL) 1.35 ± 0.44 1.67 ± 0.49 0.000*
Ln (C peptide 60’, ng/mL) 1.58 ± 0.42 1.91 ± 0.46 0.000*
Ln (C peptide 120’, ng/mL) 1.46 ± 0.46 1.82 ± 0.46 0.000*
InsAUC30/GluAUC30 (mU/mmol) 4.18 ± 2.80 7.08 ± 5.02 0.000*
InsAUC120/GluAUC120 (mU/mmol) 5.60 ± 3.09 10.44 ± 4.97 0.000*
Sqrt HOMA-β 7.94 ± 1.88 10.45 ± 2.83 0.000*
Sqrt DI30 21.79 ± 6.27 18.47 ± 6.75 0.000*
Sqrt DI120 25.33 ± 5.97 21.59 ± 8.13 0.000*
Ln [(ΔIns30/ΔGlu30)/HOMA-IR] 2.01 ± 0.91 1.58 ± 0.84 0.000*
Total cholesterol (TC), mmol/L 5.41 ± 0.95 5.56 ± 1.09 0.113
Log (triglyceride [TG]) mmol/L) 0.08 ± 0.22 0.26 ± 0.27 0.000*
Log (HDL-C, mmol/L) 0.12 ± 0.10 0.08 ± 0.08 0.000*
LDL-C, mmol/L 2.73 ± 0.68 2.94 ± 0.73 0.001*
Log (TG/HDL-C) −0.04 ± 0.28 0.18 ± 0.30 0.000*
TC/HDL-C 4.12 ± 0.94 4.62 ± 0.94 0.000*
LDL-C/HDL-C 2.10 ± 0.67 2.45 ± 0.64 0.000*
* Significant results: p < 0.05
Zhou et al. Lipids in Health and Disease  (2016) 15:104 Page 5 of 9
AUROC < 0.70), LDL-C/HDL-C (0.60 < AUROC < 0.70),
and HDL-C (AUROC < 0.50) were lower (Table 5,
Fig. 1).
In women, the AUROC for TG/HDL-C was 0.70 (95 %
CI: 0.65–0.76), and the AUROCs for TC/HDL-C, LDL-C/
HDL-C, and TG were relatively smaller (0.60 < AUROC <
0.70). In men, the AUROCs for TG/HDL-C and TG were
small (AUROC < 0.50).
4. Association of lipid ratios with islet β cell function
in a population with different levels of glucose
tolerance
In the whole population, TG/HDL, LDL-C/HDL-C
and TG were significantly associated with HOMA-β
(Table 6). In the binary multivariable logistic regression
model analysis, TG/HDL-C, LDL-C/HDL-C and TG
were negatively associated with HOMA-β, independent
of age, sex, BMI, glucose profile and IR (Table 7). The
associations among TG/HDL, LDL-C/HDL-C, TG and
HOMA-β still existed when the subjects were grouped
by sex, both in female and male subjects. The next step
was to explore whether TG/HDL-C and TG could be
acceptable predictors of fasting β cell dysfunction.
In all of the subjects, TG/HDL-C, TC/HDL-C, LDL/
HDL-C, and TG were significantly associated with the
indices of early-phase insulin secretion function (DI30,
[ΔIns30/ΔGlu30]/HOMA-IR) (Table 6). Considering the
confounding factors, such as age, BMI, waist circumfer-
ences, and hip circumference, in the multivariable logis-
tic regression model, the lipid ratios and TG were not
significantly associated with the indices of early-phase
insulin secretion function (Table 7).
TG/HDL-C and TG were significantly positively asso-
ciated with DI120, and were independent of age, BMI,
waist circumference, hip circumference, glucose profile
and IR. TC/HDL-C and LDL/HDL-C was not associated
with DI120 (Table 7). The associations among TG/HDL,
TG and DI120 still existed when the subjects were
grouped by sex, both in female and male subjects. The
Table 3 Single factor analysis: association of lipid ratios, TG, clinical features and insulin resistance
Total population Female (n = 310) Male (n = 169)
OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Log (TG/HDL-C) 14.38 (7.00–29.51) 0.000* 17.68 (6.83–45.76) 0.000* 19.17 (5.72–64.28) 0.000*
TC/HDL-C 1.78 (1.45–2.20) 0.000* 2.03 (1.54–2.67) 0.000* 1.69 (1.20–2.37) 0.003*
LDL-C/HDL-C 2.26 (1.68–3.03) 0.000* 2.74 (1.86–4.03) 0.000* 2.00 (1.23–3.25) 0.005*
Log TG 22.18 (9.30–52.93) 0.000* 24.77 (7.80–76.72) 0.000* 27.27 (6.50–114.32) 0.000*
Log HDL-C 0.01 (0.001–0.06) 0.000* 0.003 (0.00–0.05) 0.000* 0.01 (0.00–0.22) 0.005*
Sex 0.68 (0.46–0.99) 0.042* —— —— —— ——
Age, years 0.99 (0.98–1.01) 0.267 1.02 (0.99–1.04) 0.094 0.94 (0.91–0.97) 0.000*
BMI, kg/m2 1.36 (1.27–1.45) 0.000* 1.29 (1.19–1.39) 0.000* 1.59 (1.36–1.85) 0.000*
Waist circumference, cm 1.07 (1.05–1.10) 0.000* 1.08 (1.06–1.11) 0.000* 1.09 (1.05–1.13) 0.000*
Hip circumference, cm 1.06 (1.04–1.09) 0.000* 1.08 (1.05–1.11) 0.000* 1.06 (1.02–1.10) 0.001*
Systolic BP, mm Hg 1.00 (0.99–1.01) 0.790 0.99 (0.99–1.01) 0.705 1.01 (0.99–1.03) 0.273
Diastolic BP, mm Hg 1.00 (0.99–1.03) 0.383 1.01 (0.99–1.03) 0.389 1.01 (0.98–1.04) 0.658
Diabetes 4.63 (2.75–7.82) 0.000* 4.25 (2.18–8.30) 0.000* 6.62 (2.71–16.15) 0.000*
Pre-diabetes 2.15 (1.42–3.25) 0.000* 2.24 (1.35–3.72) 0.002* 2.44 (1.14–5.25) 0.022*
* Significant results: p < 0.05
Table 4 Multivariable binary logistic regression analysis: the associations of lipid ratios, TG and insulin resistance
Total population Female Male
OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Log (TG/HDL-C) 6.27 (2.86–13.76) 0.000* 5.91 (2.12–16.46) 0.001* 4.58 (1.18–17.85) 0.028*
TC/HDL-C 1.39 (1.09–1.75) 0.006* 1.39 (1.03–1.88) 0.031* 1.36 (0.89–2.07) 0.117
LDL-C/HDL-C 1.63 (1.17–2.27) 0.004* 1.63 (1.06–2.51) 0.025* 1.57 (0.85–2.90) 0.147
Log TG 7.79 (3.06–19.83) 0.000* 6.94 (2.01–23.98) 0.002* 5.43 (1.14–25.97) 0.034*
Log HDL-C 0.31 (0.13–0.72) 0.310 0.03 (0.00–0.61) 0.023* 0.12 (0.00–11.36) 0.360
* Significant results: p < 0.05
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next step was to explore whether TG/HDL-C and TG
could be good predictors of total phase β cell dysfunction.
5. Comparison of area under ROCs and optimal
cut-offs for predictors of islet β cell dysfunction in a
population with continuous glucose tolerance status
The AUROCs of TG/HDL-C, LDL-C/HDL-C and TG
for basal β cell secretion were small (AUROC < 0.50);
therefore, lipid ratios could not be predictors of basal β
cell dysfunction. TG/HDL-C and TG also could not be
acceptable predictors of total phase insulin secretion
(0.60 < AUROC < 0.70). When the population was di-
vided by sex, both in women and in men, the AUROCs
for TG/HDL-C, LDL-C/HDL-C, and TG were small
(AUROC < 0.50).
Discussion
The study showed that insulin resistance, the lipid ratios
(TG/HDL-C, TC/HDL-C, LDL-C/HDL-C) and TG in-
creased, while basal, early-phase, and total phase insulin
secretion decreased in the population with different
glucose tolerance status from normal plasma glucose to
diabetes. TG/HDL-C and TG could be serum predictors
of insulin resistance in the whole population (TG/HDL-
C: AUROC: 0.71, 95 % CI: 0.66–0.75; TG: AUROC: 0.71,
95 % CI: 0.65–0.75); the optimal cut-offs for TG/HDL
and TG were 1.11 and 1.33 mmol/L, respectively. Many
studies have shown that increasing TG and decreasing
HDL-C could cause insulin resistance. When circulating
TG was at high levels, heparin activated lipoprotein
lipase to increase intravascular lipolysis of TG, thus
increasing the risk of tissue exposure to free fatty acids
(FFAs). High FFAs could result in insulin resistance via
oxidative stress pathways [10, 23]. Previous studies have
suggested that the prediction of lipid ratios for IR was
influenced by confounding factors, such as sex, age, and
BMI. In our multivariable analysis, considering the
confounding factors, such as sex, age, BMI, and plasma
glucose profiles, the associations among TG/HDL-C, TG
and IR remained. In the present study, the plasma
glucose spectrum of the subjects was closer to that in
the real population, ranging from normal glucose toler-
ance to diabetes. The study was the first in a population
with different levels of glucose tolerance demonstrating
that TG/HDL-C and TG could be predictors of IR, the
Table 5 Area under the receiver operating characteristics curves
(ROCs) of the lipid markers for insulin resistance in the whole
population
AUROC (95 % CI) P-value
Log (TG/HDL-C) 0.71 (0.66–0.75) 0.000*
TC/HDL-C 0.66 (0.61–0.71) 0.000*
LDL-C/HDL-C 0.65 (0.60–0.70) 0.000*
Log TG 0.71 (0.65–0.75) 0.000*
Log HDL-C 0.37 (0.32–0.42) 0.000*
* Significant results: p < 0.05
Fig. 1 Area under the receiver operating characteristics curves (AUROCs) of the lipid markers for insulin resistance
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results were in agreement with previous studies based
on normal plasma glucose Chinese populations [11–14].
The present study explored the associations between
lipid ratios and insulin secretion function in different
phases, TG/HDL-C and TG were significantly negatively
associated with basal insulin secretion and positively
associated with total-phase insulin secretion. The lipid
ratio could not be a reliable marker of β cell function in
the population. Lipid ratios were not correlated with
early-phase insulin secretion, the result was not in ac-
cordance with study in normoglycemic and pre-diabetic
Japanese subjects, which showed that TG/HDL-C and
TG were negatively associated with early-phase insulin
secretion [2]. Considering that our subjects had new
onset pre-diabetes/diabetes, the total insulin secretion
increased under the conditions of hyperglycemia. Among
these new onset patients, insulin secretion was affected by
insulin sensitivity. In the present study, although the indi-
ces (DI30, [ΔIns30/ΔGlu30]/HOMA-IR, DI120) had already
been adjusted according to insulin sensitivity, the effect of
insulin sensitivity on insulin secretion could not be en-
tirely ignored. Although in our former cohort study of
patients with type 2 diabetes, high baseline log (TG)/
HDL-C ratio could be a predictor of decreased β cell func-
tion [17], in the present study the AUROCs of TG/HDL-
C and TG for β cell function were relatively low, the
predictive accuracy of TG/HDL-C and TG for β cell
function was limited. The role of lipid ratios for predicting
β cell function is still controversial in population in differ-
ent ethics and in different glucose tolerances, a recent
study in normoglycemic African American women showed
that TG/HDL-C could predict β cell function [16]. A cross-
sectional study in normoglycemic Chinese subjects sug-
gested that there was no relationship between TG/HDL-C
and β cell function [24].
The study had some limitations. This study was a cross-
sectional study to investigate the relationship between
lipid and insulin resistance, β cell function, however, longi-
tudinal study was more convincing than cross-sectional
study. We cannot assess the lifestyle like exercise and the
Table 6 Single factor analysis: association of lipid ratios, TG, clinical features and insulin secretion in different phases
HOMA-β DI30 (ΔIns30/Glu30)/HOMA-IR DI120
OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Log (TG/HDL-C) 0.46 (0.25–0.83) 0.010* 4.20 (2.22–7.94) 0.000* 2.66 (1.45–4.88) 0.002* 5.67 (2.94–10.92) 0.000*
TC/HDL-C 0.89 (0.74–1.07) 0.226 1.54 (1.26–1.89) 0.000* 1.36 (1.21–1.66) 0.002* 1.61 (1.31–1.97) 0.000*
LDL-C/HDL-C 0.76 (0.58–1.00) 0.050 1.72 (1.30–2.29) 0.000* 1.47 (1.11–1.94) 0.007* 1.80 (1.35–2.40) 0.000*
Log TG 0.41 (0.20–0.83) 0.013* 5.80 (2.68–12.54) 0.000* 3.24 (1.57–6.72) 0.002* 8.01 (3.62–17.72) 0.000*
Log HDL-C 3.95 (0.57–27.31) 0.164 0.15 (0.02–1.09) 0.061 0.26 (0.04–1.82) 0.175 0.07 (0.01–0.52) 0.010*
Sex 2.48 (1.69–3.66) 0.000* 1.30 (0.90–1.90) 0.176 1.39 (0.95–2.04) 0.089 1.57 (1.07–2.30) 0.021*
Age, years 1.05 (1.03–1.07) 0.000* 1.04 (1.02–1.06) 0.000* 1.04 (1.02–1.06) 0.000* 1.05 (1.03–1.07) 0.000*
BMI, kg/m2 0.91 (0.87–0.96) 0.000* 1.10 (1.04–1.15) 0.000* 1.07 (1.02–1.13) 0.006* 1.11 (1.06–1.18) 0.000*
Waist circumference, cm 0.99 (0.97–1.01) 0.270 1.04 (1.02–1.06) 0.000* 1.03 (1.01–1.05) 0.007* 1.03 (1.01–1.06) 0.001*
Hip circumference, cm 0.99 (0.97–1.01) 0.250 1.03 (1.01–1.05) 0.003* 1.02 (1.00–1.04) 0.052 0.01 (1.01–1.04) 0.012*
Systolic BP, mm Hg 1.01 (0.10–1.02) 0.093 1.02 (1.01–1.03) 0.004* 1.01 (1.00–1.02) 0.032* 1.01 (1.00–1.02) 0.009*
Diastolic BP, mm Hg 1.01 (0.99–1.02) 0.513 1.01 (0.99–1.03) 0.414 1.01 (0.99–1.03) 0.281 1.01 (0.99–1.03) 0.276
Diabetes 4.22 (2.51–7.09) 0.000* 129.66 (44.21–380.26) 0.000* 79.69 (30.21–210.23) 0.000* 141.19 (51.76–385.18) 0.000*
Pre-diabetes 2.07 (1.37–3.13) 0.001* 8.80 (5.35–14.46) 0.000* 5.77 (3.62–9.21) 0.000* 14.68 (8.55–25.23) 0.000*
HOMA-IR 0.68 (0.60–0.76) 0.000* 2.98 (2.08–4.28) 0.000* 2.46 (1.70–3.57) 0.000* 3.07 (2.10–4.48) 0.000*
* Significant results: p < 0.05
Table 7 Multivariable binary logistic regression analysis: the association of lipid ratios, TG and insulin secretion in different phases
HOMA-β DI30 (ΔIns30/Glu30)/HOMA-IR DI120
OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value OR (95 % CI) P-value
Log (TG/HDL-C) 0.27 (0.12–0.57) 0.001* 1.79 (0.79–4.04) 0.164 0.90 (0.40–2.04) 0.806 2.46 (1.06–5.74) 0.036*
TC/HDL-C 0.74 (0.59–0.94) 0.743 1.12 (0.86–1.46) 0.392 0.97 (0.75–1.25) 0.792 1.09 (0.82–1.46) 0.548
LDL-C/HDL-C 0.58 (0.41–0.81) 0.001* 1.15 (0.79–1.67) 0.470 0.94 (0.66–1.36) 0.751 1.07 (0.71–1.61) 0.744
Log TG 0.22 (0.90–0.54) 0.001* 2.15 (0.84–5.49) 0.109 0.97 (0.97–0.38) 0.949 2.84 (1.04–7.72) 0.041*
Log HDL-C 6.78 (0.71–64.58) 0.096 1.17 (0.08–16.24) 0.908 2.60 (0.20–33.19) 0.462 0.81 (0.04–14.83) 0.886
* Significant results: p < 0.05
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status of menopause in women exactly, which may be
confounders in the study. In future, further study should
be conduct to confirm the conclusion.
Conclusion
The present study was the first in a population with differ-
ent levels of glucose tolerance demonstrating that TG/
HDL-C and TG could be predictors of IR. TG/HDL-C
and TG were significantly negatively associated with basal
insulin secretion and positively associated with total-phase
insulin secretion, however, the lipid ratio could not be a
reliable marker of β cell function in the population.
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